Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
Apeiron Therapeutics, a biomarker-driven cancer therapy developer with operations in Shanghai, China, and San Francisco,...
Clinical trial approval / initiation
Epigenic Therapeutics Receives Approval for EPI-003 Clinical Study in New Zealand
Shanghai-based Epigenic Therapeutics, a biotechnology company specializing in the development of novel gene modulation therapies,...
Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
China’s Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from...
Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
Holland-based Xeltis AG has announced the enrollment of the first patient in a US-staged pivotal...
Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Huadong Medicine’s HDM1005 Receives FDA Approval for MASH Clinical Study
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...
Beijing Wantai Receives NMPA Clearance for Nine-Valent HPV Vaccine Targeting Male Population
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a leading Chinese pharmaceutical company, has...
Hasten Biopharmaceutical Initiates Phase III Clinical Trial for Lerodalcibep in China
China-based Hasten Biopharmaceutical Co., Ltd, a comprehensive biopharmaceutical company co-established by CBC Group, has announced...
CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...
Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...
Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044
Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that...
Jiangsu Hengrui Receives NMPA Approval for SHR-2173 Clinical Trial in ITP
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...
Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...
Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC
Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...
ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...
J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials
US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Trial of mRNA Vaccine SYS6026
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...